Alastair D. Reith is Senior Scientific Director, Novel Human Genetics Research Unit, GlaxoSmithKline Pharmaceuticals R&D. Dr. Reith has over 30 years’ experience in kinase signalling drug discovery & signalling research – gained in pharmaceutical industry, charitable, and academic research sectors in UK, China and North America.
Alastair has extensive experience in leading drug discovery & development programs for neurodegenerative diseases and forging a network of successful long-term external alliances with academic collaborators, platform technology partners and not-for-profit organisations that has yielded scientific breakthroughs to enable & expedite identification of clinical candidate compounds and their progression to clinical trials.
He has also served on both Institute and grant review panels for BBSRC, as well as review panels & expert advisory groups for a range of Research funding organisations in the charitable sector and UK Research Excellence Framework. Prior to joining GSK, he was a NATO postdoctoral fellow at Mount Sinai Hospital, Toronto, and Assistant Member at Ludwig Institute, University College London. Alastair received his PhD (Biochemistry) from Imperial College London.
